Thane Wettig

This profile gathers the share dealings of Thane Wettig in Kyntra Bio, Inc., where the filings describe the role as senior executive. In total, 59 filings cover trades dated from 22 June 2020 to 6 September 2026.

Market trades split into 5 purchases (€194k) and 11 sales (€372k). On balance, insiders were net sellers of €178k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 41 share grants.

Half of the purchases are above €30k and half below. Clusters matter here: 1 out of 5 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 9 September 2026 with a share grant (€1,539) in Kyntra Bio, Inc. The latest purchase dates back some time: it was published 340 days ago, on 17 November 2025. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.